Effectiveness, safety and tolerability of a complex homeopathic medicinal product in the prevention of recurrent acute upper respiratory tract infections in children: a multicenter, open, comparative, randomized, controlled clinical trial

Table 4 Individual complaints

Individual complaints	Visit	Absence of complaint				χ ²-Test
		CalSuli-4-02 N = 99		Control N = 101		(df) statistics	p
		N	%	N	%	(df) statistics	p
Fatigability	Baseline (day 0)	42	42.4	41	40.6	-	-
	2^nd FU (day 21)	72	72.7	61	60.4	(2) 4.140	0.1262
	3^rd FU (3 months p-t)	68	68.7	64	63.4	(2) 1.498	0.4729
	Termination (6 months p-t)	81	81.8	73	72.3	(1) 2.776	0.0957
Cough	Baseline (day 0)	41	41.4	49	48.5	-	-
	2^nd FU (day 21)	84	84.9	84	83.2	(2) 0.166	0.9203
	3^rd FU (3 months p-t)	91	91.9	83	82.2	(2) 5.015	0.0815
	Termination (6 months p-t)	89	89.9	95	94.1	(2) 2.576	0.2759
Nasal discharge (blocked/runny nose)	Baseline (day 0)	37	37.4	37	36.6	-	-
	2^nd FU (day 21)	82	82.8	72	71.3	(2) 4.130	0.1268
	3^rd FU (3 months p-t)	82	82.8	80	79.2	(2) 0.628	0.7305
	Termination (6 months p-t)	88	88.9	85	84.2	(2) 1.165	0.5585
Appetite disorder	Baseline (day 0)	39	39.4	39	38.6	-	-
	2^nd FU (day 21)	75	75.8	58	57.4	(1) 7.707	0.0055
	3^rd FU (3 months p-t)	81	81.8	64	63.4	(1) 9.052	0.0026
	Termination (6 months p-t)	82	82.8	69	68.3	(1) 6.099	0.0135
Irritability	Baseline (day 0)	51	51.5	52	51.5	-	-
	2^nd FU (day 21)	78	78.8	70	69.3	(1) 2.412	0.1204
	3^rd FU (3 months p-t)	81	81.8	76	75.3	(1) 1.395	0.2375
	Termination (6 months p-t)	88	88.9	84	83.2	(1) 1.573	0.2098

Df degree of freedom, FU follow-up, p-t post-treatment, χ ² chi-square, ITT intention-to-treat analysis